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Abstract 
Background Sodium–glucose co-transporter 2 (SGLT2) inhibitors may have renal protective effects 
in people with impaired kidney function. We assessed the use of SGLT2 inhibitors in people with type 
2 diabetes with or without renal impairment [defined as estimated glomerular filtration rate (eGFR) of 
≥ 30 and < 60 ml/min/1.73 m2 and/or UACR > 300 and ≤ 5000 mg/g] by conducting a systematic 
review and meta-analysis of available studies. 
Methods Randomised controlled trials (RCTs) were identified from MEDLINE, EMABASE, Web of 
Science, the Cochrane Library, and search of bibliographies to March 2017. No relevant observational 
study was identified. Summary measures were presented as mean differences and narrative synthesis 
performed for studies that could not be pooled. 
Results 42 articles which included 40 RCTs comprising 29,954 patients were included. In populations 
with renal impairment, SGLT2 inhibition compared with placebo was consistently associated with an 
initial decrease in eGFR followed by an increase and return to baseline levels. In pooled analysis of 
17 studies in populations without renal impairment, there was no significant change in eGFR 
comparing SGLT2 inhibitors with placebo (mean difference, 0.51 ml/min/1.73 m2; 95% CI: -0.69, 
1.72; p=403). SGLT2 inhibition relative to placebo was associated with preservation in serum creatine 
levels or initial increases followed by return to baseline levels in patients with renal impairment, but 
levels were preserved in patients without renal impairment. In populations with or without renal 
impairment, SGLT2 inhibitors (particularly canagliflozin and empagliflozin) compared with placebo 
were associated with decreased urine albumin, improved albuminiuria, slowed progression to 
macroalbuminuria, and reduced the risk of worsening renal impairment, the initiation of kidney 
transplant, and death from renal disease. 
Conclusions Emerging data suggests that with SGLT2 inhibition, renal function seems to be 
preserved in people with diabetes with or without renal impairment. Furthermore, SGLT2 inhibition 
prevents further renal function deterioration and death from kidney disease in these patients. 
 
Keywords: SGLT2 inhibitor, type 2 diabetes, renal impairment 
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Introduction 
There is a large and growing burden of diabetes globally. In 2013, 382 million people had diabetes 
and this number has been projected to increase to 592 million by 2035.1 With increasing life 
expectancy and prevalence of type 2 diabetes, complications and deaths attributable to diabetes will 
also increase, especially if there is no concomitant improvement in the health system for its early 
management.1 Chronic kidney disease (CKD) is a common complication in people with type 2 
diabetes2 and may in some cases progress to end-stage renal disease, which requires dialysis and/or 
kidney transplant which are associated with high healthcare costs.3-5 Indeed, a recent population-based 
study showed that the costs associated with the treatment of end-stage renal disease in patients with 
type 2 diabetes was ten times that of type 2 diabetes patients without renal failure.5  
The kidneys are involved not just in the pharmacokinetic processing of many antidiabetic agents,6-9 
but also in the mechanisms of action of some classes of antidiabetic drugs.10  Therefore, prescribing 
antidiabetic drugs in patients with diabetes and CKD can be very challenging, with special concerns 
regarding safety and efficacy and the need for appropriate dosage adjustment according to the renal 
function. For patients with type 2 diabetes and CKD, there are limited treatment options for glycaemic 
control.  
Sodium–glucose co-transporter 2 (SGLT2) inhibitors, are novel therapeutic agents for the 
treatment of type 2 diabetes and work by inhibiting glucose reabsorption and induce excretion of 
glucose in the urine, thereby reducing circulating plasma glucose levels.11 Their mechanisms of action 
are independent of insulin action or beta-cell function and their use is associated with reductions in 
HbA1c levels, weight and systolic blood pressure.10 Data from phase III trials suggest that SGLT2 
inhibitors might achieve their beneficial effects without having significant adverse effects. Treatment 
with canagliflozin was shown to be associated with decreased albuminuria and an early decrease in 
estimated glomerular filtration rate (eGFR).12,13 Yale and colleagues reported that a lower proportion 
of participants in the canagliflozin 100 and 300 mg groups progressed from normoalbuminuria to 
micro- or macro-albuminuria, or from micro- to macro-albuminuria compared with those in the 
placebo group.13  In the CANagliflozin CardioVascular Assessment Study (CANVAS), there were 
significant reductions in albuminuria and the albumin-to-creatinine ratio for canagliflozin 100 mg and 
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300 mg doses, compared with placebo.12 For nearly 2 decades, the use of Renin-Angiotensin-
Aldosterone system (RAAS) inhibition has been employed in the management of diabetes to reduce 
the rate of progression of diabetes nephropathy.14,15 The kidney plays a key role in modulating glucose 
levels by mediating the reabsorption of glucose back into the plasma, after filtration of the blood. 
Similarly, SGLT2-inhibitors cause vaso-constriction of the afferent arterioles, thus decreasing the 
hyper-filtration in the glomerulus. This then can lead to a decrease in the rate of progression of 
proteinuria.8 These new type 2 diabetes drugs may therefore offer an alternative option for renal 
protection. Since the mechanism of renal protection of SGLT2 inhibitors seems to occur 
independently of their glycaemic controlling effect, it is plausible that their effect on prevention of 
deterioration of renal function could be maintained; even when they are used in patients with impaired 
renal function, where they are usually deemed not to be effective for glucose control. Currently 
SLGT2 inhibitors are only licenced for use in glycaemic control and hence contra-indicated in people 
with eGFR less than 45 ml/min/1.73 m2. In the absence of treatment options for the prevention of 
deterioration of renal impairment other than RAAS inhibition, the use of SGLT2 inhibitors show 
some promise in this area. To our knowledge, the only RCT designed to assess whether an SGLT2 
inhibitor compared with a placebo, has a renal protective effect in participants with type 2 diabetes 
mellitus, chronic kidney disease and macroalbuminuria, is the “Evaluation of the Effects of 
Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy 
(CREDENCE) study”. However, this study is not due to be completed until 2019. (ClinicalTrials.gov 
Identifier: NCT02065791). There are currently no systematic reviews or meta-analysis of RCTs on 
this subject.  In this context, we aimed to pool available interventional evidence in one updated 
systematic meta-analysis. Our aim was to determine if the use of SGLT2 inhibition prevents further 
renal function deterioration in people with type 2 diabetes with or without renal impairment. 
 
Methods 
Data sources and search strategy  
This review was conducted using a predefined protocol and in accordance with PRISMA 
(Appendices 1). We sought studies published before March 06, 2017 (date last searched) using 
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MEDLINE, EMBASE, Web of Science, and the Cochrane electronic databases. The computer-based 
searches combined terms related to the intervention (e.g., SGLT2 inhibitors, dapagliflozin, 
canagliflozin, empagliflozin); population (e.g., type 2 diabetes, renal impairment, CKD, renal 
insufficiency); and outcomes (e.g., serum creatinine, urine albumin-to-creatinine ratio) in humans, 
without any language restriction. Details on the search strategy are provided in Appendix 3. Two 
authors working independently screened the titles and abstracts of all initially identified studies 
according to the selection criteria. Full texts were retrieved from studies that satisfied all selection 
criteria. Bibliographies of selected studies and relevant reviews identified on the topic area were 
manually scanned for additional publications.  
 
Study selection and eligibility criteria  
Intervention studies were eligible if they were randomised controlled, open or blinded, or non-
randomised trials; that assessed the effects of SGLT2 inhibitor treatment compared with a placebo or 
standard care in adults with type 2 diabetes with or without renal impairment and reported renal 
outcomes [as assessed by eGFR, blood urea nitrogen (BUN), serum creatinine, urine albumin-to-
creatinine ratio (UACR), and urine albumin or changes in the concentrations of these markers] in 
adults (≥ 18 years old) with type 2 diabetes with or without renal impairment (defined as eGFR of ≥ 
30 and < 60 ml/min/1.73 m2 and/or UACR > 300 and ≤ 5000 mg/g). Studies were excluded if they (i) 
specifically enrolled only patients with known renal insufficiency or established renal parenchymal 
disease without diabetes mellitus; (ii) recruited patients with a history of diabetic ketoacidosis, type 1 
diabetes mellitus, history of hereditary glucose-galactose malabsorption, primary renal glucosuria, or 
renal disease that required treatment with immunosuppressive; (iii) cross-sectional designs.   
 
Data extraction  
Two authors (SKK and SS) used a predesigned data extraction form to independently extract data and 
a consensus was reached in case of any inconsistency with involvement of a third (KK). Relevant 
information was extracted on study design; publication year, study year, baseline population including 
proportion of men; geographical location; average age at baseline; numbers enrolled and randomised; 
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allocation concealment; blinding; type of SGLT2 inhibitor and dosage; duration of treatment or 
follow-up; treatment comparisons; and nature of outcome and numbers. We extracted summary 
measures and risk estimates reported for fully-adjusted models, where relevant.  In the case of 
multiple publications involving the same study, the most up-to-date or comprehensive information 
was abstracted.  
 
Assessing the risk of bias  
The Cochrane Collaboration’s risk of bias tool16 was used to assess the quality of the included trials. 
This tool evaluates seven possible sources of bias which are random sequence generation, allocation 
concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete 
outcome data, selective reporting and other bias. For each individual component, studies were 
classified into low, unclear and high risk of bias.  
 
Statistical analysis  
Summary measures were presented as mean differences for continuous outcomes and risk estimates 
for categorical outcomes, where relevant. For data reported as medians, ranges, and 95% confidence 
intervals (CIs), means and standard deviations were calculated as described by Hozo and colleagues. 
17 The inverse variance weighted method was used to combine summary measures using random-
effects models to minimise the effect of between-study heterogeneity 18. Heterogeneity was assessed 
using the Cochrane χ2 statistic and the I2 statistic; and was distinguished as low (I2 ≥ 25%), moderate 
(25% < I2 ≥ 50%) or high (I2 ≥ 75%).19 Given the variety of measures reported for renal outcomes and 
inconsistent reporting by some of the trials, a formal meta-analysis could not be performed for some 
of the data. A narrative synthesis was performed for studies that could not be pooled. The findings of 
such studies were summarised in tables that included the main characteristics of the study and the 
results in natural units as reported by the investigators. All tests were two-tailed and p-values of 0.05 
or less were considered significant. STATA release 13 (Stata Corp, College Station, Texas, USA) was 
used for all statistical analyses. 
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Results 
Study identification and selection 
Figure 1 shows the flow of studies through the review. The search of relevant databases and manual 
scanning of reference lists of relevant studies identified 1171 potentially relevant articles. After the 
initial screening of which was based on titles and abstracts, 119 articles remained for full text 
evaluation. Following detailed evaluation, 77 articles were excluded because (i) they were based on 
reviews (n=32); (ii) the outcomes reported were not relevant (n=29); (iii) included populations not 
relevant to review (n=12); and (iv) duplicate studies (n=4). The remaining 42 articles met the 
inclusion criteria and were included in the review. 
 
Study characteristics and quality 
The 42 articles included in the review involved a total of 40 RCTs comprising 29,954 participants13,20-
60 (Table 1). All 40 trials were conducted in populations with type 2 diabetes; however, 6 trials were 
based in populations who also had impaired kidney function or prevalent kidney disease (n=2,768), 
whilst 37 trials were conducted in populations not specifically diagnosed with kidney disease. Four 
articles were based on two trials which reported results for different time periods.13,20,43,44 All included 
studies were double-blinded RCTs; however, majority of trials extended treatment in an open-label 
manner after the initial double-blind phase. Except for three trials that were specifically conducted in 
Japan or Finland, all the other trials were conducted in multiple countries. The type of SGLT2 
inhibitors used included dapagliflozin, canagliflozin, and empagliflozin. Luseogliflozin, ipragliflozin, 
and tofogliflozin which are SGLT2 inhibitors developed and approved in Japan, were employed by 
some of the trials conducted in Japan. The treatment duration ranged from 24 weeks to 2.6 years. 
Using the Cochrane Collaboration tool, all trials demonstrated low risk of bias in the areas of random 
sequence generation and blinding of participants & personnel, whiles majority of trials demonstrated 
an unclear risk of bias in the area of blinding of outcome assessments. (Appendix 3).  
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Change in estimated GFR 
Populations with renal impairment In three studies (n=478),22-24 reductions in eGFR levels were seen 
with SGLT2 inhibitors relative to placebo during the first few weeks of treatment, but the levels 
increased thereafter and returned towards baseline values by the end of treatment period. In the 26-
week, double-blind, core treatment trial phase of the 52-week study by Yale and colleagues,13 
decreases in eGFR from baseline were observed for all treatment groups. However, the reductions 
were larger in the canagliflozin 100 and 300 mg groups compared with the placebo group (least 
square percent mean change, -9.1% versus -10.1% versus -4.5% respectively). The decreases in eGFR 
with canagliflozin treatment were substantial during the first weeks of treatment and then trended 
towards baseline values at the end of the 26-week treatment period. In the article that reported study 
findings over the entire 52 weeks of treatment, eGFR levels returned to baseline values at the end of 
52 weeks.20 
Populations without renal impairment In pooled analysis of 17 studies, there was no significant 
change in eGFR comparing SGLT2 inhibitors with placebo (mean difference, 0.51 ml/min/1.73 m2; 
95% CI: -0.69, 1.72; p=403). There was evidence of substantial heterogeneity between contributing 
studies I2=75% (60, 84%; p<0.001) (Figure 2). On exclusion of the study that reported imprecise 
estimates (very wide 95% CIs),50 the finding was similar (mean difference, 0.46 ml/min/1.73 m2; 95% 
CI: -0.75, 1.66; p=459) and evidence of substantial heterogeneity remained  I2=76% (62, 85%; 
p<0.001). In a subgroup analysis by the class of SGLT2 inhibitors, no significant change was 
observed in eGFR for any of the SGLT2 inhibitors evaluated (Figure 3). In pooled analysis of two 
studies that reported estimates as mean percent changes,28,37 100 mg of canagliflozin compared with 
placebo was not associated with a significant change in eGFR (mean percent difference, -1.11; 95% 
CI: -2.97, 0.75; p=242). In the 12-week double-blind, three-arm parallel-group, placebo-controlled 
trial by Wilding and colleagues,30 only minor changes were observed in eGFR at the end of treatment 
(mean change, -0.84, 1.45, and -0.58 ml/min/1.73 m2 for 10 mg dapagliflozin, 20 mg dapagliflozin, 
and placebo groups respectively). In the 52-week randomised, double-blind, phase III non-inferiority 
trial that compared canagliflozin with glimepiride in patients with type 2 diabetes inadequately 
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controlled with metformin (CANTATA-SU),38 decreases in eGFR were marked for glimepiride 
compared with 100 mg and 200 mg of canagliflozin (mean change, -5.1, -1.7, and -3.0 ml/min/1.73 
m2 respectively). In the trial of dapagliflozin versus glipizide in patients with type 2 diabetes 
inadequately controlled with metformin monotherapy,55 the decrease in eGFR was more dramatic for 
glipizide compared with dapagliflozin at the end of 52 weeks therapy (mean change, -5.4 and -0.5 
ml/min/1.73 m2 respectively) (Table 2). 
 
Change in BUN  
Populations with renal impairment In pooled analysis of two studies (n=226), a significant increase 
in BUN was seen with SGLT2 inhibitors compared with placebo (mean difference, 2.06 mg/dl; 95% 
CI: 0.88, 3.25; p=0.001).22,24 However, in the initial 24 week trial by Haneda and colleagues22 to 
evaluate the efficacy and safety of luseogliflozin compared to placebo in patients with moderate renal 
impairment, BUN levels increased until week 12 and remained stable thereafter. Yale and colleagues 
also showed canagliflozin 100 and 300 mg to be associated with increases in BUN relative to placebo 
at the end of the 52 week period (least square percent mean change, 12% versus 17.3% versus 5.4% 
respectively).20 
Populations without renal impairment Pooled analysis of seven studies (n=1039) showed a 
significant increase in BUN when SGLT2 inhibitors were compared with placebo (mean difference, 
1.80 mg/dl; 95% CI: 1.37, 2.24; p<0.001) (Figure 4). In the 16-week placebo-controlled trial by 
Kashiwagi and colleagues to assess the efficacy and safety of 50 mg ipragliflozin as monotherapy in 
Japanese patients;39 though there was an increase in BUN associated with ipragliflozin treatment, the 
increase was not dependent on duration of treatment and the levels returned to almost baseline levels 
during the 4-week follow-up period after completion of treatment. There was no evidence of 
substantial heterogeneity between contributing studies I2=7% (0, 73%; p=0.373). In pooled analysis of 
five studies that reported BUN in mmol/l,32-36 10 mg dapagliflozin compared with placebo was 
associated with a significant increase in BUN (mean difference, 0.48 mmol/l; 95% CI: 0.32, 0.64; 
p<0.001). There was no evidence of heterogeneity between contributing studies I2=0% (0, 79%; 
p=0.432). In pooled analysis of five studies that reported estimates as mean percent changes,27,28,37,46,47 
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100 mg of canagliflozin compared with placebo was associated with a significant increase in BUN 
(mean percent difference, 11.00; 95% CI: -6.51, 15.50; p<0.001). There was evidence of 
heterogeneity between contributing studies I2=66% (12, 87%; p=0.018). Table 2 reports changes in 
BUN for trials that could not be pooled. When canagliflozin was compared with glimepiride in the 
CANTATA-SU trial,38 increases in BUN were noted with canagliflozin compared with glimepiride 
(mean percent change, 15.3, 22.0, and 6.50 for 100 mg canagliflozin, 300 canagliflozin, and 
glimepiride respectively). Seino and colleagues in their trial of luseogliflozin monotherapy at doses of 
up to 10 mg in Japanese patients with type 2 diabetes,52 demonstrated increases in BUN in the 1 and 
10 mg groups compared with placebo. In another trial by the same authors, 2.5 mg luseogliflozin 
compared with placebo was associated with a significant increase in BUN.53 Nauck and colleagues 
demonstrated increased mean values of BUN with dapagliflozin treatment compared with glipizide in 
patients with type 2 diabetes inadequately controlled with metformin monotherapy.55  
 
Change in serum creatinine 
Populations with renal impairment Treatment with ipragliflozin was associated with increase in 
serum creatinine levels in the short term, but levels returned to baseline values at the end of the 
treatment period (mean difference, 0.04 mg/dl; 95% CI: -0.00, 0.08).24 In a 52-week phase III trial, 
serum creatinine levels hardly changed with 2.5 mg luseogliflozin treatment (mean difference, 0.04 
mg/dl; 95% CI: 0.00, 0.07).22 In another trial, an increase in serum creatinine level was observed in 
the first week with dapagliflozin treatment (mean difference, 0.03 mg/dl; 95% CI: -0.09, 0.14), but 
this increase remained stable during the remainder of the study.23 Canagliflozin 100 and 300 mg was 
shown to be associated with increases in serum creatinine compared with placebo at the end of a 52 
week treatment period (least square percent mean change, 6.6% versus 11.2% versus 5.2% 
respectively).20 
Populations without renal impairment In pooled analysis of eight studies, there was no significant 
change in serum creatinine when comparing SGLT2 inhibitors with placebo (mean difference, 0.00 
mg/dl; 95% CI: -0.01, 0.01; p=0.724) and there was no evidence of substantial heterogeneity between 
contributing studies I2=28% (0, 67%; p=0.209) (Figure 5). In pooled analysis of six studies that 
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reported serum creatinine in µmol/l,32-36,44 10 mg dapagliflozin or empagliflozin compared with 
placebo was not associated with a significant change in serum creatinine (mean difference, 0.042 
µmol/l; 95% CI: -0.838, 0.922; p=926). There was no evidence of heterogeneity between contributing 
studies I2=0% (0, 75%; p=0.659). In pooled analysis of five studies that reported estimates as mean 
percent changes,27,28,37,46,47 100 mg of canagliflozin compared with placebo was not associated with a 
significant change in serum creatinine (mean percent difference, 0.068; 95% CI: -1.084, 1.220; 
p=0.908). There was no evidence of heterogeneity between contributing studies I2=2% (0, 80%; 
p=0.394).  
Results of individual trials which could not be pooled are reported in Table 2. There were no 
significant changes in serum creatinine when luseogliflozin at doses of 0.5, 2.5, and 5 mg were 
compared to placebo.51 In two other trials by Seino and colleagues, treatment with luseogliflozin 
compared with placebo was not associated with significant changes in serum creatinine.52,53 Nauck 
and colleagues demonstrated no significant change in serum creatinine for dapagliflozin treatment 
compared with glipizide.55 No significant change was observed for serum creatinine comparing 
empagliflozin with glimepiride.59 
 
Change in urine albumin-creatinine ratio 
Populations with renal impairment Table 2 reports changes in UACR for trials that reported these 
outcomes. At the end of a 24 week treatment period, canagliflozin 100 and 300 mg were associated 
with greater decreases in UACR compared with placebo (median percent reduction, -29.9% versus -
20.9% versus -7.5% respectively).13 At 52 weeks follow-up in the same trial, canagliflozin 100 and 
300 mg were still associated with decreases in UACR (median percent change, -16.4% and -28.0% 
respectively); however, an increase was seen with placebo (median percent change, 19.7%).20 At 104 
weeks, dapagliflozin 5 mg compared with placebo was associated with an increase in UACR from 
baseline, but this was not statistically significant (mean difference, 8.30 mg/g; 95% CI: -262.4, 279.0; 
p=0.952); whiles dapagliflozin 10 mg compared with placebo decreased UACR from baseline (mean 
difference, -81.39 mg/g; 95% CI: -412.25, 249.47; p=0.632).23 At the end of a 24 week treatment 
period, ipragliflozin 50 mg compared with placebo was associated with a decrease in UACR (mean 
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difference, -55.18 mg/g Cr; 95% CI: -412.25, 249.47; p=0.173).24 Urine albumin-creatinine ratio 
improved with 25 mg empagliflozin compared with placebo at week 52 (adjusted mean difference, -
183.78; 95% CI: -305.18, -62.38; p=0.0031).25 In a double-blind phase III trial that compared the 
efficacy and safety of empagliflozin with glimepiride as add-on to metformin in patients with 
type 2 diabetes with and without renal impairment, a marked decrease in UACR was observed with 
empagliflozin, whiles a marked increase was observed with glimepiride in patients with UACR > 300 
mg/g at baseline.59 
Populations without renal impairment In pooled analysis of three trials,40,41,50 50 mg ipragliflozin 
compared with placebo was not associated with a significant change in UACR (mean difference, -2.78 
mg/g Cr; 95% CI: -14.79, 9.23; p=0.650). There was no evidence of heterogeneity between 
contributing studies I2=0% (0, 90%; p=0.408). Pooled analysis of two trials that reported UACR in 
mg/g, 34,60 showed no significant change in UACR when comparing dapagliflozin or canagliflozin 
with placebo (mean difference, -3.28 mg/g; 95% CI: -18.86, 12.30; p=0.680). Results of trials that 
could not be pooled are reported in Table 2. In a phase IIb trial that evaluated the efficacy, safety, 
tolerability and pharmacokinetics of empagliflozin, mean UACR values decreased from baseline in 
the intervention and placebo groups.29 In the CANTATA-SU trial,38 there were only small changes in 
UACR values comparing canagliflozin with glimepiride (mean change: -0.9, -0.1, and 0.7 g/mol for 
100 mg canagliflozin, 300 canagliflozin, and glimepiride respectively). In a 52-week trial in patients 
receiving metformin therapy, dapagliflozin treatment dramatically decreased UACR when compared 
with glipizide.55 In the double-blind phase III trial that compared the efficacy and safety of 
empagliflozin with glimepiride as add-on to metformin in patients with type 2 diabetes, no significant 
change was observed for UACR comparing empagliflozin treatment with that of glimepiride.59 
 
Urine albumin 
Populations with renal impairment At the end of a 52 week treatment period, canagliflozin 100 and 
300 mg were associated with decreases in urine albumin (median percent change, -34.4% and -49.0% 
respectively); however, an increase was seen with placebo (median percent change, 14.3%).13 At 24 
weeks, luseogliflozin 2.5 mg compared with placebo was associated with a non-significant decrease in 
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creatinine-corrected urine albumin (mean difference, -25.11 mg/g Cr; 95% CI: -146.50, 96.30; 
p=0.683).22 Yale and colleagues evaluated progression of albuminuria from baseline, and showed that 
a lower proportion of participants in canagliflozin 100 and 300 mg groups progressed compared with 
placebo (shift from normoalbuminuria to micro or macroalbuminuria/microalbuminuria to 
macroalbuminuria, 5.1% versus 8.3% versus 11.8% respectively).13 Similar results were observed 
when empagliflozin 25 mg was compared with placebo: (shift from no albuminuria to 
macroalbuminuria, 12.2% versus 22.2%); (shift from microalbuminuria to macroalbuminuria, 2.0% 
versus 11.4%); (shift from macroalbuminuria to microalbuminuria, 32.6% versus 8.6%); and (shift 
from microalbuminuria to no albuminuria, 27.5% versus 21.4%).25 
Populations without renal impairment In the CANVAS trial,26 there was a reduced risk of the 
outcome of progression to albuminuria when canagliflozin 100 or 300 mg was compared with placebo 
(hazard ratio, 0.73; 95% CI, 0.67, 0.79). Canagliflozin 100 or 300 mg compared with placebo was 
also associated with an increased risk of regression of albuminuria (hazard ratio, 1.70; 95% CI, 1.51, 
1.91). 
 
Other outcomes 
Populations with renal impairment In the EMPA-REG OUTCOME trial, empaglifozin 10 or 25 mg 
compared with placebo was associated with a reduced risk of incident or worsening nephropathy 
(defined as progression to macroalbuminuria, a doubling of the serum creatinine level, accompanied 
by an eGFR of ≤ 45 ml/min/1.73 m2, the initiation of renal-replacement therapy; or death from renal 
disease) (hazard ratio, 0.58; 95% CI, 0.47, 0.71; p<0.001). There was also a reduced risk of the 
composite outcome of a doubling in serum creatinine, initiation of renal replacement therapy, or death 
due to renal disease; when empaglifozin 10 or 25 mg compared with placebo (hazard ratio, 0.51; 95% 
CI, 0.31, 0.85; p=0.010).21  
Populations without renal impairment In the CANVAS trial, canagliflozin 100 or 300 mg compared 
with placebo was associated with a reduced risk of the composite outcome of sustained 40% reduction 
in eGFR, the need for renal-replacement therapy, or death from renal causes (hazard ratio, 0.60; 95% 
CI, 0.47, 0.77).26 
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Discussion 
Key findings 
In this systematic review and meta-analysis from available RCTs, we have compared SGLT2 
inhibition with placebo or standard care in people with type 2 diabetes with or without renal 
impairment and assessed relevant renal outcomes. In the greater majority of trials of type 2 diabetes 
patients with renal impairment, SGLT2 inhibitors compared with placebo were associated with initial 
decreases in eGFR during the first few weeks of therapy and there were greater decreases with higher 
doses compared with lower doses of SGLT2 inhibitors. However, the levels returned to baseline 
values at the end of the treatment period. For trials of populations without renal impairment, renal 
function as measured by eGFR seemed to be preserved with SGLT2 inhibitor treatment and this was 
consistent for the different classes of SGLT2 inhibitors. There were rather dramatic decreases in 
eGFR when standard antidiabetic drugs such as glimepiride or glipizide were compared with SGLT2 
inhibitors. In populations with renal impairment, SGLT2 inhibition was associated with preservation 
of serum creatinine levels or there were initial increases followed by return to baseline levels. 
However, in populations without renal impairment, levels of serum creatinine did not change 
significantly with SGLT2 inhibitor therapy. Evidence from a limited number of studies however 
showed increases in levels of BUN with SGLT2 treatment compared with placebo in populations with 
renal impairment. In populations without renal impairment, there were significant increases in BUN 
with SGLT2 inhibitor treatment. In patients with renal impairment, whereas majority of trials showed 
decreases in UACR, others showed an increase in UACR; however, majority of the results were not 
statistically significant. However, based on the statistically significant results from two trials,13,25 the 
overall findings suggest that SGLT2 inhibitors (particularly canagliflozin and empagliflozin) 
compared with placebo are associated with improvement in UACR in populations with renal 
impairment. The greater majority of trials conducted in populations without renal impairment did not 
demonstrate any significant changes in UACR with SGLT2 inhibitor treatment, except for one trial 
which showed a dramatic decrease in UACR with dapagliflozin treatment compared with glipizide.55  
In populations with or without renal impairment, treatment with SGLT2 inhibitors was associated 
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with decrease in urine albumin levels, slowed progression to macroalbuminuria, and improved 
albuminuria. Finally, empaglifozin or canagliflozin compared with placebo was associated with a 
reduced risk of worsening renal impairment, initiation of renal-replacement therapy, or death from 
renal disease. 
 
Comparison with previous studies 
A number of limited reviews have been conducted on the topic and some of our findings concur with 
the results of these studies. However, our findings which were based on type 2 diabetes patients with 
or without renal impairment, provide several relevant findings that have not been previously reported. 
In pooled individual participant data analysis of four RCTs that enrolled patients with type 2 diabetes 
and stage 3 CKD, canagliflozin 100 and 300 mg decreased eGFR, whiles increases were seen with the 
placebo.61 In the same study, canagliflozin 100 and 300 mg compared with placebo showed reductions 
in albuminuria. In another pooled individual participant data analysis of five RCTs that enrolled 
patients with type 2 diabetes and prevalent microalbuminuria or macroalbuminuria, empagliflozin 
compared with placebo significantly decreased UACR values in the macroalbuminuria group.62 Our 
findings which were based on a larger number of trials consistently showed initial decreases in levels 
of eGFR followed by an increase and return to baseline values with SGLT2 inhibition in populations 
with renal impairment. There was preservation of serum creatinine levels or there were initial 
increases followed by return to baseline levels with SGLT2 inhibition. However, for populations 
without renal impairment, eGFR as well as other renal biomarkers such as serum creatine and UACR 
were preserved with SGLT2 inhibition. Finally, recent results from the EMPA-REG OUTCOME and 
CANVAS trials indicate that SGLT2 inhibition slows down the progression of albuminuria and 
worsening kidney impairment, initiation of kidney transplant, and death from kidney disease in type 2 
diabetes patients with or without renal impairment.21,26  
 
Potential explanation of findings 
Sodium–glucose co-transporter 2 inhibitors work by targeting renal tubular glucose reabsorption. 
Their action is based on the blockage of SGLT2 sodium-glucose cotransporters that are located in the 
16 
 
tubular cells of the proximal convoluted tubule, thereby inducing glucosuria.63 Although the efficacy 
of SGLT2 inhibitors is affected by renal function,23 emerging data indicates that  SGLT2 inhibition 
has a reno-protective effect.63 In patients with diabetes, there is an increase in the expression of 
sodium-glucose co-transport receptors in the proximal tubules leading to an increased re-absorption of 
sodium and glucose in 1:1 stoichiometry in the proximal tubule 3. This leads to a decreased delivery 
of sodium to the macular densa. As a result of this, less sodium is available for the breakdown of ATP 
to produce adenosine which is a potent vasoconstrictor 4. Therefore, the afferent arteriole will dilate 
leading to increased pressure and hyper filtration in the glomerulus, which stimulates the cascade of 
pathophysiological changes that cause diabetes nephropathy. Sodium-glucose linked transporter 2 
inhibitors enhance delivery of sodium to the macular densa which leads to increase breakdown of 
ATP producing adenosine. This then causes vaso-constriction of the afferent arterioles, thus 
decreasing the hyper-filtration in the glomerulus. This then can lead to a decrease in the rate of 
progression of proteinuria. The overall evidence shows that SGLT2 inhibition causes reductions in 
eGFR. However, these reductions are usually seen in the early phases of treatment initiation with 
levels subsequently returning to normal during treatment. Yale and colleagues showed a reduction in 
eGFR with canagliflozin therapy in the first weeks of therapy, but the levels returned to normal values 
over the entire treatment period.13 Yamout and colleagues in pooled analysis of four trials showed that 
the declines in eGFR associated with canagliflozin therapy were seen during early treatment initiation; 
however, these levels returned to baseline values over time.61 There have been suggestions that these 
initial reductions in eGFR are related to the volume depletion associated with the diuretic properties 
of SGLT2 inhibitors. The increase in levels of the blood renal biomarkers therefore reflect this 
volume depletion.20  
 
Implications of findings 
In end-stage renal disease (ESRD), the need for Renal Protection Therapy (RRT) can lead to 
significant deterioration of the patient’s quality of life and exerts significant cost on the health 
system.64 For the past two decades, clinicians have merely depended on RAAS inhibition as a target 
for preventing the deterioration of diabetes nephropathy, albeit with some good results. The current 
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results suggest that SGLT2 inhibitor therapy in diabetes and renal impairment could prevent further 
renal deterioration. The current evidence suggests that the protective effects of SGLT2 inhibitors 
could be attributed to canagliflozin and empagliflozin, two of the well-known SGLT2 inhibitors used 
in clinical practice. Further robust interventional evidence such as those from the ongoing 
CREDENCE study, may help confirm the reno-protective effect of SGLT2 inhibitor therapy. If this is 
confirmed, it will be a welcome addition to the limited armamentarium of therapeutic options in this 
area. Given the high mortality rates associated with CKD and the healthcare costs associated with the 
management of CKD in patients with type 2 diabetes,3-5 the potential benefits of SGLT2 inhibitors in 
reducing the progression of CKD will be useful for clinical practice. In recent years, more and more 
people with diabetes and its complications such as nephropathy are now managed in primary care and 
only referred to specialist units for consideration of RRT in the very late stages. The early use of 
SGLT2 inhibitors in the prevention of renal deterioration in addition to their glycaemic control 
deserves further study. 
 
Strengths and limitations 
Strengths of the current study included clearly defined populations which were based on people with 
type 2 diabetes and with or without renal impairment. Our review was prespecified to include all 
observational study designs as well as RCTs published on the topic; therefore our search strategy was 
very detailed and spanned several databases. We were however unable to identify any relevant 
observational study that met the inclusion criteria. Our review was comprehensive and to our 
knowledge included the greater majority of relevant trials published on the topic. An assessment of 
the methodological quality of included trials were conducted and they were all of adequate quality. In 
addition, we reported on a wide range of renal outcomes. Some limitations also deserve consideration. 
Majority of trials included in the review extended treatment in an open-label manner after the initial 
double-blind core phase, which could have limited the validity of the results. However, majority of 
these trials reported findings for both phases, results which seemed to follow similar trends. Though 
we performed quantitative synthesis of the data where possible, inconsistent reporting of outcome 
measures from some of the studies precluded pooling of all available data. This also prevented us 
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from conducting subgroup analyses by several relevant clinical characteristics. Due to limited data 
available, head-to-head comparisons of the different SGLT2 inhibitors could not be explored. There 
was evidence of substantial between study heterogeneity in some of the analyses and which couldn’t 
be explored because of the limited data. The current findings should stimulate further research on the 
role of SGLT2 inhibition on renal outcomes in people with diabetes, particularly those with renal 
impairment. 
 
Conclusions 
In conclusion, emerging data suggests that SGLT2 inhibition prevents further renal function 
deterioration in people with type 2 diabetes with or without renal impairment. In patients with renal 
impairment, though treatment with SGLT2 inhibitors are associated with reductions in eGFR, the 
reductions are not substantial and are usually seen in the early phases of treatment initiation, with 
levels returning to baseline values with time. However, for populations without renal impairment, 
renal function seems preserved with SGLT2 inhibitors. In populations with or without renal 
impairment, SGLT2 inhibition is also associated with reduction in UACR, slows down the 
progression of albuminuria, improves albuminuria, and is also associated with reduced risk of 
progression to a doubling of the serum creatinine levels, initiation of kidney transplant, and death 
from kidney disease  
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Figure 1. Selection of studies included in the meta-analysis 
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Figure 2. Mean difference in estimated glomerular filtration levels comparing SGLT2 inhibition with 
placebo in populations without renal impairment  
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Figure 3. Mean difference in estimated glomerular filtration levels comparing SGLT2 inhibition with 
placebo in populations without renal impairment, by class of SGLT2 inhibitor 
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Lu, 2016
Subtotal
Empagliflozin
Haring, 2014
Haring, 2013
Kovacs, 2014
Rosenstock, 2014
Rosenstock, 2015
Tikkanen, 2015
Kadowaki, 2014
Ridderstrale, 2014
Subtotal
Canagliflozin
Wilding, 2013
Forst, 2014
Subtotal
Tofogliflozin
Kaku, 2014
Subtotal
Author, year of 
publication
Dapagliflozin 10 mg
Dapagliflozin 10 mg
Ipragliflozin 50 mg
Ipragliflozin 50 mg
Ipragliflozin 50 mg
Ipragliflozin 50 mg
Empagliflozin 10 mg
Empagliflozin 10 mg
Empagliflozin 10 mg
Empagliflozin 10 mg
Empagliflozin 10 mg
Empagliflozin 10 mg
Empagliflozin 10 mg
Empagliflozin 25 mg
Canagliflozin 100 mg
Canagliflozin 100 mg
Tofogliflozin 10 mg
Intervention, dosage
89
151
62
97
166
87
217
226
165
186
169
276
109
765
157
113
59
Intervention
group
91
146
67
54
77
83
207
225
165
188
170
271
109
780
156
115
57
Placebo 
group
0.20 (-2.85, 3.25)
-1.20 (-3.93, 1.53)
-0.58 (-2.61, 1.46)
-3.33 (-6.42, -0.24)
0.56 (-2.17, 3.29)
-2.00 (-4.10, 0.10)
8.42 (-5.15, 21.99)
-1.29 (-3.58, 1.00)
-0.90 (-3.26, 1.46)
0.60 (-1.31, 2.51)
-1.60 (-4.51, 1.31)
0.40 (-1.92, 2.72)
4.80 (2.13, 7.47)
3.88 (2.23, 5.53)
0.06 (-2.03, 2.15)
3.50 (2.20, 4.80)
1.44 (-0.12, 3.01)
0.30 (-2.65, 3.25)
2.30 (-0.79, 5.39)
1.25 (-0.88, 3.39)
-2.12 (-5.32, 1.08)
-2.12 (-5.32, 1.08)
Mean difference (95% CI)
0-15 -10 -5 2.5 5 10 15 20 25
Mean difference (ml/min/1.73 m2)
 
CI, confidence interval (bars); SGLT2, sodium–glucose co-transporter 2 
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Figure 4. Mean difference in BUN comparing SGLT2 inhibition with placebo in populations without 
renal impairment 
List, 2009
Kashiwagi, 2015 (a)
Kashiwagi, 2015 (b)
Kashiwagi, 2015 (c)
Lu, 2016
Kaku, 2014
Rosenstock, 2012 (b)
Subtotal
Author, year of 
publication
Dapagliflozin 10 mg
Ipragliflozin 50 mg
Ipragliflozin 50 mg
Ipragliflozin 50 mg
Ipragliflozin 50 mg
Tofogliflozin 10 mg
Canagliflozin 100 mg
Intervention, dosage
47
62
97
166
87
59
64
Intervention
group
54
67
54
77
83
57
65
Placebo
group
2.99 (1.69, 4.29)
1.80 (0.73, 2.87)
1.90 (0.85, 2.95)
1.50 (0.59, 2.41)
2.20 (1.01, 3.39)
1.70 (0.55, 2.86)
0.87 (-0.32, 2.06)
1.80 (1.37, 2.24)
Mean difference (95% CI)
0-2.5 2.5 5 7.5
Mean difference, mg/dl
 
BUN, blood urea nitrogen; CI, confidence interval (bars); SGLT2, sodium–glucose co-transporter 2 
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Figure 5. Mean difference in creatinine levels comparing SGLT2 inhibition with placebo in 
populations without renal impairment  
List, 2009
Kashiwagi, 2015 (a)
Kashiwagi, 2015 (b)
Kashiwagi, 2015 (c)
Lu, 2016
Kaku, 2014
Rosenstock, 2012 (b)
Inagaki, 2014
Subtotal
Author, year of 
publication
Dapagliflozin 10 mg
Ipragliflozin 50 mg
Ipragliflozin 50 mg
Ipragliflozin 50 mg
Ipragliflozin 50 mg
Tofogliflozin 20 mg
Canagliflozin 100 mg
Canagliflozin 100 mg
Intervention, dosage
47
62
97
166
87
60
64
90
Intervention
group
54
67
54
77
83
57
65
93
Placebo
group
-0.02 (-0.05, 0.01)
0.02 (-0.00, 0.04)
-0.01 (-0.03, 0.01)
0.02 (0.00, 0.03)
-0.02 (-0.05, 0.01)
0.00 (-0.04, 0.04)
-0.03 (-0.06, 0.10)
0.00 (-0.02, 0.02)
0.00 (-0.01, 0.01)
Mean difference (95% CI)
0-.12 -.08 -.04 .04 .08 .12 .16 .2
Mean difference, mg/dl
 
CI, confidence interval (bars); SGLT2, sodium–glucose co-transporter 2 
 
 
 
 
Table 1. Characteristics of clinical trials of SGLT2 inhibitors included in systematic review 
Author, year of 
publication 
 
Name of study  
 
 
 
 
 
 
 
 
 
 
 
Study design 
 
 
 
 
 
 
 
 
 
 
 
Patient population 
 
 
 
Location 
 
 
 
 
 
 
 
 
 
Baseline 
year of 
study 
 
 
 
 
 
 
 
 
 
 
Age group 
(years) 
Males 
(%) 
 
Allocation 
concealment 
 
 
Blinding to 
subjects 
 
 
 
Blinding to 
carers 
 
Medication 
and dosage 
 
 
 
 
 
 
 
 
 
 
Duration of therapy 
(weeks) 
 
 
 
Treatment 
arm (N) 
 
 
 
 
 
 
 
 
 
 
Placebo 
arm (N) 
With renal impairment 
Yale, 2013; Yale, 2014 - Randomised, double-blind with 
placebo 
T2DM with inadequate glycaemic 
control and stage 3 CKD 
89 centres in 19 
countries 
NR ≥ 25 60.6 Unclear Yes Yes Canagliflozin, 
100 and 300 mg 
26 (core period) 
26 (extension period) 
90/89 90 
Barnett, 2014 EMPA-REG 
RENAL 
Randomised, double-blind with 
placebo 
T2DM and stage 3 CKD 127 centres in 15 
countries 
2010-2012 ≥ 18 56.7 Adequate Yes Yes Empagliflozin, 
25 mg 
52 187 187 
Kohan, 2014 - Randomised, double-blind with 
placebo 
T2DM with inadequate glycaemic 
control and estimated GFR 30 to 
59 ml/min/1.73 m2 
111 sites in 13 
countries 
2008-2009 ≥ 18 65.1 Unclear Yes Yes Dapagliflozin, 5 
and 10 mg 
24 (short-term 
period) 
28 (long-term period) 
2nd year (extension 
period) 
83/85 84 
Kashiwagi, 2015 LANTERN Randomised, double-blind with 
placebo 
T2DM and estimated GFR 30 to 
59 ml/min/1.73 m2 
Japan 2011-2012 20-74 78.0 Unclear Yes Yes Ipragliflozin, 50 
mg 
24 (core period) 
28 (extension period) 
58 23 
Wanner, 2016 EMPA-REG 
OUTCOME 
Randomised, double-blind with 
placebo 
T2DM and prevalent kidney 
disease 
590 sites in 42 
countries 
2010-2013 ≥ 18 67.8 Adequate Yes Yes Empagliflozin, 
10 or 25 mg 
2.6 years 1,212 607 
Haneda, 2016 - Randomised, double-blind with 
placebo 
T2DM and estimated GFR ≥ 30 to 
< 60 ml/min/1.73 m2 
Japan NR ≥ 20 76.6 Adequate Yes Yes Luseogliflozin, 
2.5 mg 
24 (core period) 
28 (extension period) 
95 50 
With no renal impairment  
Wilding, 2009 - Randomised, double-blind with 
placebo 
T2DM poorly controlled with high 
insulin plus oral antidiabetic drugs 
26 centres in US 
and Canada 
2006-2007 18-75 59.2 Unclear Yes Yes Dapagliflozin, 
10 and 20 mg 
12 24 / 24 23 
List, 2009 - Randomised, double-blind with 
placebo 
T2DM 98 centres in US, 
24 in Canada, 8 
in Mexico, 3 in 
Puerto Rico 
2005-2006 18-79 54.0 Unclear Yes Yes Dapagliflozin, 
2.5, 5, 10, 20, 
and 50 mg 
12 59 / 58 / 47 / 
59 / 56 
54 
Ferrannini, 2010 - Randomised, double-blind with 
placebo 
T2DM treatment naïve 
inadequately controlled with diet 
and exercise alone 
85 centres in US, 
Canada, Mexico, 
Russia 
2007-2008 18-77 48.2 Unclear Yes Yes Dapagliflozin, 
2.5, 5, and 10 mg 
24 65 / 64 / 70 75 
Bailey, 2010 - Randomised, double-blind with 
placebo 
T2DM with inadequate glycaemic 
control on metformin therapy 
80 sites 2007-2008 18-77 53.5 Adequate Yes Yes Dapagliflozin, 
2.5, 5, and 10 mg 
24 137 / 135 / 
135 
137 
Nauck, 2011 - Randomised, double-blind with 
glipizide 
T2DM inadequately controlled 
with metformin 
 2008 ≥ 18 55.1 Adequate Yes Yes Dapagliflozin, 
2.5/5/10 mg 
52 406 408 
Author, year of 
publication 
 
Name of study  
 
 
 
 
 
 
 
 
 
 
 
Study design 
 
 
 
 
 
 
 
 
 
 
 
Patient population 
 
 
 
Location 
 
 
 
 
 
 
 
 
 
Baseline 
year of 
study 
 
 
 
 
 
 
 
 
 
 
Age group 
(years) 
Males 
(%) 
 
Allocation 
concealment 
 
 
Blinding to 
subjects 
 
 
 
Blinding to 
carers 
 
Medication 
and dosage 
 
 
 
 
 
 
 
 
 
 
Duration of therapy 
(weeks) 
 
 
 
Treatment 
arm (N) 
 
 
 
 
 
 
 
 
 
 
Placebo 
arm (N) 
Strojek, 2011 - Randomised, double-blind with 
placebo 
T2DM with inadequate glycaemic 
control on glimepiride 
84 sites 2008-2009 ≥ 18 47.7 Adequate Yes Yes Dapagliflozin, 
2.5, 5, and 10 mg 
24 154 / 145 / 
151 
146 
Bolinder, 2012 - Randomised, double-blind with 
placebo 
T2DM 40 sites in 5 
countries 
2009 30-75 55.6 Adequate Yes Yes Dapagliflozin, 
10 mg 
24 89 91 
Rosenstock, 2012 - Randomised, double-blind with 
placebo 
T2DM with inadequate glycaemic 
control on pioglitazone 
105 sites 2008-2009 ≥ 18 49.5 Unclear Yes Yes Dapagliflozin, 5 
and 10 mg 
48 141 / 140 139 
Rosenstock, 2012 (b) - Randomised, double-blind with 
placebo 
T2DM inadequately controlled 
with metformin 
85 sites in 12 
countries 
NR 18-65 52.0 Unclear Yes Yes Canagliflozin, 
50, 100, 200 and 
300 mg 
12 64 / 64 / 65 
64 
65 
Stenlof, 2013 CANTATA-M Randomised, double-blind with 
placebo 
T2DM inadequately controlled 
with diet and exercise 
17 countries NR 18-80 44.2 Unclear Yes Yes Canagliflozin, 
100 and 300 mg 
26  197 / 197 192 
Lavalle-Gonzalez, 2013 - Randomised, double-blind with 
placebo 
T2DM with inadequate glycaemic 
control on metformin therapy 
169 centres in 22 
countries 
2010-2012 18-80 47.1 Adequate Yes Yes Canagliflozin, 
100 and 300 mg 
52 296 / 295 139 
Ferrannini, 2013 - Randomised, double-blind with 
placebo 
T2DM 75 centres in 13 
countries 
NR 18-79 52.0 Adequate Yes Yes Empagliflozin, 5, 
10, and 25 mg 
12 81 / 81 / 82 82 
Bode, 2013 - Randomised, double-blind with 
placebo 
T2DM with inadequate glycaemic 
control on glucose lowering agents 
90 centres in 17 
countries 
2010-2011 55-80 55.5 Adequate Yes Yes Canagliflozin, 
100 and 300 mg 
26 241 / 236 237 
Cefalu, 2013 CANTATA-SU Randomised, double-blind with 
glimepiride 
T2DM with inadequate glycaemic 
control on glucose lowering agents 
157 centres in 19 
countries 
2009-2011 18-80 52.0 Adequate Yes Yes Canagliflozin, 
100 and 300 mg 
52 483 / 485 482 
Wilding, 2013 CANTATA-
MSU 
Randomised, double-blind with 
placebo 
T2DM inadequately controlled 85 centres in 11 
countries 
2010-2012 18-80 51.0 Adequate Yes Yes Canagliflozin, 
100 and 300 mg 
52 157 / 156 156 
Inagaki, 2014 - Randomised, double-blind with 
placebo 
T2DM 31 insitutions in 
Japan 
 
2011-2012 ≥ 20 70.5 Adequate Yes Yes Canagliflozin, 
100 and 200 mg 
24 90 / 89 93 
Kovacs, 2014 EMPA-REG PIO Randomised, double-blind with 
placebo 
T2DM 69 centres in 8 
countries 
NR ≥ 18 48.4 Adequate Yes Yes Empagliflozin, 
10 and 25 mg 
24 165 / 168 165 
Ridderstrale, 2014 - Randomised, double-blind with 
glimepiride 
T2DM 173 sites in 23 
countries 
2010-2011 ≥ 18 55.1 Adequate Yes Yes Empagliflozin, 
25 mg 
104 765 780 
Author, year of 
publication 
 
Name of study  
 
 
 
 
 
 
 
 
 
 
 
Study design 
 
 
 
 
 
 
 
 
 
 
 
Patient population 
 
 
 
Location 
 
 
 
 
 
 
 
 
 
Baseline 
year of 
study 
 
 
 
 
 
 
 
 
 
 
Age group 
(years) 
Males 
(%) 
 
Allocation 
concealment 
 
 
Blinding to 
subjects 
 
 
 
Blinding to 
carers 
 
Medication 
and dosage 
 
 
 
 
 
 
 
 
 
 
Duration of therapy 
(weeks) 
 
 
 
Treatment 
arm (N) 
 
 
 
 
 
 
 
 
 
 
Placebo 
arm (N) 
Haring, 2013; Haering, 
2015 
EMPA-REG 
METSU; 
EMPA-REG 
EXTEND 
METSU 
Randomised, double-blind with 
placebo 
T2DM inadequately controlled 149 centres in 12 
countries 
2010-2012 ≥ 18 51.0 Adequate Yes Yes Empagliflozin, 
10 and 25 mg 
24 (core period) 
 
 
52 (extension period) 
226 / 218 
225 / 216 
225 
225 
Tikkanen, 2015 EMPA-REG BP Randomised, double-blind with 
placebo 
T2DM with hypertension Finland 2011-2012 ≥ 18 60.1 Adequate Yes Yes Empagliflozin, 
10 and 25 mg 
12 276 271 
Haring, 2014 EMPA-REG 
MET 
Randomised, double-blind with 
placebo 
T2DM inadequately controlled 148 centres in 12 
countries 
2010-2012 ≥ 18 57.0 Adequate Yes Yes Empagliflozin, 
10 and 25 mg 
24 217 / 213 207 
Forst, 2014 - Randomised, double-blind with 
placebo 
T2DM inadequately controlled 74 centres in 11 
countries 
NR 18-80 63.2 Adequate Yes Yes Canagliflozin, 
100 and 300 mg 
52 113 / 114 115 
Kaku, 2014 - Randomised, double-blind with 
placebo 
T2DM inadequately controlled 
with diet/exercise alone 
33 sites in Japan 2010-2012 20-74 65.1 Adequate Yes Yes Tofogliflozin, 
10, 20, and 40 
mg 
24 59 / 60 / 59 57 
Kadowaki, 2014 - Randomised, double-blind with 
placebo 
T2DM 32 centres in 
Japan 
NR 18-80 75.0 Adequate Yes Yes Empagliflozin, 5 
and 10 mg 
12 110 / 109 109 
Rosenstock, 2014 - Randomised, double-blind with 
placebo 
T2DM inadequately controlled 
and obese 
104 centres in 14 
countries 
2011-2013 56.7* 45.0 Adequate Yes Yes Empagliflozin, 
10 and 25 mg 
52 186 / 189 188 
Seino, 2014 - Randomised, double-blind with 
placebo 
T2DM 40 sites in Japan 2009 20-74 NR Adequate Yes Yes Luseogliflozin, 
0.5, 2.5, and 5 
mg 
12 61 / 61 / 61 56 
Seino, 2014 (b) - Randomised, double-blind with 
placebo 
T2DM 41 sites in Japan 2010-2011 20-74 NR Adequate Yes Yes Luseogliflozin, 
1, 2.5, 5, and 10 
mg 
12 56 / 56 / 54 / 
58 
58 
Seino, 2014 (c) - Randomised, double-blind with 
placebo 
T2DM 23 sites in Japan 2011-2012 ≥ 20 73.4 Adequate Yes Yes Luseogliflozin, 
2.5 mg 
24 79 79 
Rosenstock, 2015 - Randomised, double-blind with 
placebo 
T2DM inadequately controlled on 
basal insulin 
97 centres in 7 
countries 
2009-2012 58.8* 56.0 Adequate Yes Yes Empagliflozin, 
10 and 25 mg 
78 169 / 155 170 
Kashiwagi, 2015 (a) BRIGHTEN Randomised, double-blind with 
placebo 
T2DM 22 sites in Japan 2010 NR NR Unclear Yes Yes Ipragliflozin, 50 
mg 
16 62 67 
Author, year of 
publication 
 
Name of study  
 
 
 
 
 
 
 
 
 
 
 
Study design 
 
 
 
 
 
 
 
 
 
 
 
Patient population 
 
 
 
Location 
 
 
 
 
 
 
 
 
 
Baseline 
year of 
study 
 
 
 
 
 
 
 
 
 
 
Age group 
(years) 
Males 
(%) 
 
Allocation 
concealment 
 
 
Blinding to 
subjects 
 
 
 
Blinding to 
carers 
 
Medication 
and dosage 
 
 
 
 
 
 
 
 
 
 
Duration of therapy 
(weeks) 
 
 
 
Treatment 
arm (N) 
 
 
 
 
 
 
 
 
 
 
Placebo 
arm (N) 
Kashiwagi, 2015 (b) SPOTLIGHT Randomised, double-blind with 
placebo 
T2DM inadequately controlled Japan 2010 ≥ 20 73.7 Adequate Yes Yes Ipragliflozin, 50 
mg 
24 97 54 
Kashiwagi, 2015 (c) EMIT Randomised, double-blind with 
placebo 
T2DM inadequately controlled 35 sites in Japan 2010-2012 ≥ 20 NR Adequate Yes Yes Ipragliflozin, 50 
mg 
24 166 77 
Lu, 2016 - Randomised, double-blind with 
placebo 
T2DM 30 sites in Korea 
and Taiwan 
2011-2013 NR NR Adequate Yes Yes Ipragliflozin, 50 
mg 
22 87 83 
Neal, 2017 CANVAS 
Program 
Randomised, double-blind with 
placebo 
T2DM with high cardiovascular 
risk, estimated GFR > 30 
667 centres in 30 
countries 
2009, 2014 ≥ 30 64.2 Adequate Yes Yes Canagliflozin, 
100/300 mg 
188.2 5,795 4,347 
 
*, are mean ages; CANTATA-M, CANagliflozin Treatment And Trial Analysis– Monotherapy; CANTATA-MSU, CANagliflozin Treatment And Trial Analysis – Metformin plus SUlphonylurea; CANTATA-SU, 
CANagliflozin Treatment And Trial Analysis versus SUlphonylurea; CANVAS, Canagliflozin Cardiovascular Assessment Study; CKD, chronic kidney disease; GFR, glomerular filtration rate; LANTERN, Long-Term 
ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment; NR, not reported; SGLT2, sodium–glucose co-transporter 2; T2DM, type 2 diabetes mellitus 
  
Table 2. Results of changes in outcomes in relevant trials that could not be pooled 
Author, year of 
publication 
 
Name of study 
 
Medication and dosage 
 
 
 
 
 
 
 
 
 
 
 
Duration of therapy 
(weeks) 
 
 
 
Treatment arm 
(N) 
 
 
 
 
 
 
 
 
 
 
 
 
Placebo arm (N) 
 
 
 
 
 
 
 
 
 
 
 
 
Change in treatment arm 
 
 
 
 
 
 
 
 
 
 
 
 
Change in placebo arm 
Estimated glomerular filtration rate – populations without renal impairment 
Wilding, 2009 - Dapagliflozin, 10 mg 
Dapagliflozin, 20 mg 
12 24 
24 
23 
23 
Mean change (-0.840) ml/min/1.73 m2 
Mean change (1.450) ml/min/1.73 m2 
Mean change (-0.580) ml/min/1.73 m2 
Mean change (-0.580) ml/min/1.73 m2 
Nauck, 2011 - Dapagliflozin, 2.5/5/10 mg 52 406 Glipizide arm (408) Mean (SE) change: -0.50 (0.80) ml/min/1.73 m2 
 
Mean (SE) change: -5.40 (0.80) ml/min/1.73 m2 
 
Cefalu, 2013 CANTATA-SU Canagliflozin, 100 mg 
Canagliflozin, 300 mg 
52 483 
485 
Glimepiride 482 
Glimepiride 482 
Mean change (-1.70) ml/min/1.73 m2 
Mean change (-3.00) ml/min/1.73 m2 
Mean change (-5.10) ml/min/1.73 m2 
Mean change (-5.10) ml/min/1.73 m2 
Blood urea nitrogen – populations without renal impairment 
Cefalu, 2013 CANTATA-SU Canagliflozin, 100 mg 
Canagliflozin, 300 mg 
52 483 
485 
Glimepiride 482 
Glimepiride 482 
Mean (SD) percent change: 15.30 (29.10) 
Mean (SD) percent change: 22.00 (30.80) 
Mean (SD) percent change: 6.50 (26.40) 
Mean (SD) percent change: 6.50 (26.40) 
Seino, 2014 (b) - Luseogliflozin, 1 mg 
Luseogliflozin 2.5 mg 
Luseogliflozin, 5 mg 
Luseogliflozin, 10 mg 
 
12 56 
56 
54 
58 
58 
58 
58 
58 
Least squares mean change: 1.6 (95% CI, 0.8-2.4) mg/dl 
Least squares mean change: 0.9 (95% CI, 0.1-1.7) mg/dl 
Least squares mean change: 1.4 (95% CI, 0.6-2.2) mg/dl 
Least squares mean change: 1.6 (95% CI, 0.8-2.4) mg/dl 
Least squares mean change: 0.4 (95% CI, -0.4-1.2) mg/dl 
Least squares mean change: 0.4 (95% CI, -0.4-1.2) mg/dl 
Least squares mean change: 0.4 (95% CI, -0.4-1.2) mg/dl 
Least squares mean change: 0.4 (95% CI, -0.4-1.2) mg/dl 
 
Seino, 2014 (c) - Luseogliflozin 2.5 mg 
 
24 79 79 Least squares mean difference: 1.80 (95% CI, 0.80-2.80) 
mg/dl 
 
Nauck, 2011 - Dapagliflozin, 2.5/5/10 mg 52 406 Glipizide arm (408) Mean (SE) change: -0.50 (0.80) mmol/l Mean (SE) change: 0.10 (0.07) mmol/l 
Serum creatinine – populations without renal impairment 
Author, year of 
publication 
 
Name of study 
 
Medication and dosage 
 
 
 
 
 
 
 
 
 
 
 
Duration of therapy 
(weeks) 
 
 
 
Treatment arm 
(N) 
 
 
 
 
 
 
 
 
 
 
 
 
Placebo arm (N) 
 
 
 
 
 
 
 
 
 
 
 
 
Change in treatment arm 
 
 
 
 
 
 
 
 
 
 
 
 
Change in placebo arm 
Seino, 2014  Luseogliflozin, 0.5 mg 
Luseogliflozin 2.5 mg 
Luseogliflozin, 5 mg 
 
12 61 
61 
61 
56 
56 
56 
Least squares mean change: -0.002 (95% CI, -0.02, 0.01) 
mg/dl 
Least squares mean change: 0.003 (95% CI, -0.01, 0.02) 
mg/dl 
Least squares mean change: 0.012 (95% CI, 0.00, 0.03) 
mg/dl 
Least squares mean change: -0.004 (95% CI, -0.02, 0.01) 
mg/dl 
Least squares mean change: -0.004 (95% CI, -0.02, 0.01) 
mg/dl 
Least squares mean change: -0.004 (95% CI, -0.02, 0.01) 
mg/dl 
Seino, 2014 (b) - Luseogliflozin, 1 mg 
Luseogliflozin 2.5 mg 
Luseogliflozin, 5 mg 
Luseogliflozin, 10 mg 
 
 
12 56 
56 
54 
58 
58 
58 
58 
58 
Least squares mean change: -0.021 (95% CI, -0.037, -
0.005) mg/dl 
Least squares mean change: -0.005 (95% CI, -0.021, 
0.011) mg/dl 
Least squares mean change: 0.011 (95% CI, -0.005, 
0.027) mg/dl 
Least squares mean change: 0.009 (95% CI, -0.007, 
0.025) mg/dl 
Least squares mean change: -0.005 (95% CI, -0.02, 0.011) 
mg/dl 
Least squares mean change: -0.005 (95% CI, -0.02, 0.011) 
mg/dl 
Least squares mean change: -0.005 (95% CI, -0.02, 0.011) 
mg/dl 
Least squares mean change: -0.005 (95% CI, -0.02, 0.011) 
mg/dl 
Seino, 2014 (c) - Luseogliflozin 2.5 mg 
 
24 79 79 Least squares mean difference: -0.001 (95% CI, -0.021, 
0.018) mg/dl 
 
 
Nauck, 2011 - Dapagliflozin, 2.5/5/10 mg 52 406 Glipizide arm (408) Mean (SE) change: -0.180 (1.110) µmol/l Mean (SE) change: 3.620 (0.630) µmol/l 
Ridderstrale, 2014 - Empagliflozin, 25 mg 104 765 Glimepiride arm 
(780) 
Mean (SD) change: 0.00 (13.00) µmol/l 
 
Mean (SD) change: 2.00 (9.00) µmol/l 
 
Urine albumin-to-creatinine ratio – populations with renal impairment 
Yale, 2013 - Canagliflozin, 100 mg 
Canagliflozin 300 mg 
26 90 
89 
90 
90 
Median percent change (-29.9) 
Median percent change (-20.9) 
Median percent change (-7.5) 
Median percent change (-7.5) 
Yale, 2014 - Canagliflozin 100 mg 
Canagliflozin 300 mg 
52 90 
89 
90 
90 
Median percent change (-16.4) 
Median percent change (-28.0) 
Median percentage change (19.7) 
Median percent change (19.7) 
Author, year of 
publication 
 
Name of study 
 
Medication and dosage 
 
 
 
 
 
 
 
 
 
 
 
Duration of therapy 
(weeks) 
 
 
 
Treatment arm 
(N) 
 
 
 
 
 
 
 
 
 
 
 
 
Placebo arm (N) 
 
 
 
 
 
 
 
 
 
 
 
 
Change in treatment arm 
 
 
 
 
 
 
 
 
 
 
 
 
Change in placebo arm 
Kohan, 2014 - Dapagliflozin 5 mg 
Dapagliflozin 10 mg 
 
104 83 
85 
84 
84 
Mean (SE) change: 78 (112.5) mg/g 
Mean (SE) change: -11.69 (148.6) mg/g 
Mean (SE) change: 69.7 (80.1) mg/g 
Mean (SE) change: 69.7 (80.1) mg/g 
Kashiwagi, 2015 LANTERN Ipragliflozin, 50 mg 24 58 23 Mean (SD) change: -37.1 (279.14) mg/g Cr 
 
Mean (SD) change: 18.08 (82.196) mg/g Cr 
 Barnett, 2014 EMPA-REG 
RENAL 
Empagliflozin, 25 mg 52 187 187 Adjusted mean difference comparing empagliflozin with 
placebo:  
-183.78; 95% CI: -305.18, -62.38; p=0.0031 
 
Urine albumin-to-creatinine ratio – populations without renal impairment 
Ferrannini, 2013 - Empagliflozin, 5 mg 
Empagliflozin, 10 mg 
Empagliflozin, 25 mg 
12 81 
81 
82 
82 
82 
82 
Median change (-0.340) mg/mmol 
Median change (-0.360) mg/mmol 
Median change (-1.00) mg/mmol 
Median change (-0.780) mg/mmol 
Median change (-0.780) mg/mmol 
Median change (-0.780) mg/mmol 
Cefalu, 2013 CANTATA-SU Canagliflozin, 100 mg 
Canagliflozin, 300 mg 
52 483 
485 
Glimepiride 482 
Glimepiride 482 
Mean (SE) change: -0.10 (4.70) g/mol 
Mean (SE) change: -0.90 (6.70) g/mol 
Mean (SE) change: 0.70 (15.30) g/mol 
Mean (SE) change: 0.70 (15.30) g/mol 
Nauck, 2011 - Dapagliflozin, 2.5/5/10 mg 52 406 Glipizide arm (408) Mean (SE) change: -19.00 (6.60) mg/g 
 
Mean (SE) change: -0.80 (7.10) mg/g 
 
Ridderstrale, 2014 - Empagliflozin, 25 mg 104 765 Glimepiride arm 
(780) 
Mean (SD) change: 6.70 (37.70) mg/g 
 
Mean (SD) change: 8.60 (72.60) mg/g 
 
Urine albumin-to-creatinine ratio – populations with renal impairment 
Ridderstrale, 2014 - Empagliflozin, 25 mg 16 19 Glimepiride arm 
(780) 
Mean (SD) change: -483.5 (613.7) mg/g 
 
Mean (SD) change: 380.1 (1161.5) mg/g 
 
 
CANTATA-SU, CANagliflozin Treatment And Trial Analysis versus SUlphonylurea; LANTERN, Long-Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment; SD, standard 
deviation; SE, standard error 
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Appendix 1: PRISMA checklist 
 
Section/topic 
Item 
No Checklist item 
Reported 
on page No 
Title 
Title 1 Identify the report as a systematic review, meta-analysis, or both 1 
Abstract 
Structured summary 2 Provide a structured summary including, as applicable, background, objectives, 
data sources, study eligibility criteria, participants, interventions, study appraisal 
and synthesis methods, results, limitations, conclusions and implications of key 
findings, systematic review registration number 
2 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what is already known Introduction 
Objectives 4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS) 
Introduction 
Methods 
Protocol and 
registration 
5 Indicate if a review protocol exists, if and where it can be accessed (such as web 
address), and, if available, provide registration information including 
registration number 
Methods 
Eligibility criteria 6 Specify study characteristics (such as PICOS, length of follow-up) and report 
characteristics (such as years considered, language, publication status) used as 
criteria for eligibility, giving rationale 
Methods 
Information sources 7 Describe all information sources (such as databases with dates of coverage, 
contact with study authors to identify additional studies) in the search and date 
last searched 
Methods 
Search 8 Present full electronic search strategy for at least one database, including any 
limits used, such that it could be repeated 
Appendix 2 
Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in 
systematic review, and, if applicable, included in the meta-analysis) 
Methods 
Data collection 
process 
10 Describe method of data extraction from reports (such as piloted forms, 
independently, in duplicate) and any processes for obtaining and confirming 
data from investigators 
Methods 
Data items 11 List and define all variables for which data were sought (such as PICOS, 
funding sources) and any assumptions and simplifications made 
Methods 
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and how 
this information is to be used in any data synthesis 
Methods 
Summary measures 13 State the principal summary measures (such as risk ratio, difference in means). Methods 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, 
including measures of consistency (such as I2 statistic) for each meta-analysis 
Methods 
Risk of bias across 
studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence 
(such as publication bias, selective reporting within studies) 
Methods 
Additional analyses 16 Describe methods of additional analyses (such as sensitivity or subgroup 
analyses, meta-regression), if done, indicating which were pre-specified 
Methods 
Results 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the 
review, with reasons for exclusions at each stage, ideally with a flow diagram 
Results, Figure 
1 
Study characteristics 18 For each study, present characteristics for which data were extracted (such as 
study size, PICOS, follow-up period) and provide the citations 
Results, Table 1 
Risk of bias within 
studies 
19 Present data on risk of bias of each study and, if available, any outcome-level 
assessment (see item 12). 
Results, 
Appendix 3  
Results of individual 
studies 
20 For all outcomes considered (benefits or harms), present for each study (a) 
simple summary data for each intervention group and (b) effect estimates and 
confidence intervals, ideally with a forest plot 
 
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency 
Results, Figures 
2-4;  
Risk of bias across 
studies 
22 Present results of any assessment of risk of bias across studies (see item 15) Not applicable 
Additional analysis 23 Give results of additional analyses, if done (such as sensitivity or subgroup 
analyses, meta-regression) (see item 16) 
Not applicable 
Discussion 
Summary of 
evidence 
24 Summarise the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (such as health care providers, 
users, and policy makers) 
Discussion 
Limitations 25 Discuss limitations at study and outcome level (such as risk of bias), and at 
review level (such as incomplete retrieval of identified research, reporting bias) 
Discussion 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, 
and implications for future research 
Discussion 
Funding 
3 
 
Section/topic 
Item 
No Checklist item 
Reported 
on page No 
Funding 27 Describe sources of funding for the systematic review and other support (such as 
supply of data) and role of funders for the systematic review 
Page 18 
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Appendix 2: MEDLINE literature search strategy 
 
Relevant studies published from inception to March 06, 2017 (date last searched), were identified through electronic searches not 
limited to the English language using MEDLINE, EMBASE, Web of Science, and Cochrane databases. Electronic searches were 
supplemented by scanning reference lists of articles identified for all relevant studies (including review articles), and by hand 
searching of relevant journals. The computer-based searches combined terms related to the intervention (e.g., SGLT2 inhibitors, 
dapagliflozin, canagliflozin, empagliflozin); population (e.g., type 2 diabetes, renal impairment, CKD, renal insufficiency); and 
outcomes (e.g., serum creatinine, urine albumin-to-creatinine ratio) in humans, without any language restriction. 
 
1     exp Canagliflozin/ (259) 
2     dapagliflozin.mp. (443) 
3     empagliflozin.mp. (437) 
4     exp Sodium-Glucose Transporter 2/ (904) 
5     SGLT inhibitor.mp. (37) 
6     exp Sodium-Glucose Transport Proteins/ (1865) 
7     sodium glucose-cotransporter.mp. (834) 
8     exp Diabetes Mellitus, Type 2/ (106242) 
9     exp Diabetes Mellitus/ (364281) 
10     diabetes.mp. (501764) 
11     exp Renal Insufficiency, Chronic/ (97154) 
12     exp Kidney Failure, Chronic/ (85142) 
13     exp Renal Insufficiency/ (146319) 
14     exp Kidney Diseases/ (459420) 
15     chronic renal insufficiency.mp. (4627) 
16     impaired kidney function.mp. (623) 
17     decreased kidney function.mp. (296) 
18     decreased renal function.mp. (927) 
19     exp Glomerular Filtration Rate/ (37580) 
20     1 or 2 or 3 or 4 or 5 or 6 or 7 (2662) 
21     8 or 9 or 10 (531039) 
22     11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 (478834) 
23     20 and 21 and 22 (151) 
24     limit 23 to humans (119) 
 
Each part was specifically translated for searching alternative databases. 
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Appendix 3: Assessment of risk of bias 
 
 
 
 
 
 
 
 
